Challenges, solutions, and recommendations for Alzheimer's disease combination therapy

James A. Hendrix, Randall J. Bateman, H. Robert Brashear, Cynthia Duggan, Maria C. Carrillo, Lisa J. Bain, Ronald DeMattos, Russell G. Katz, Susanne Ostrowitzki, Eric Siemers, Reisa Sperling, Ottavio V. Vitolo

Research output: Contribution to journalShort surveypeer-review

35 Scopus citations

Abstract

Given the complex neuropathology Alzheimer's disease (AD), combination therapy may be necessary for effective treatment. However, scientific, pragmatic, regulatory, and business challenges need to be addressed before combination therapy for AD can become a reality. Leaders from academia and industry, along with a former member of the Food and Drug Administration and the Alzheimer's Association, have explored these challenges and here propose a strategy to facilitate proof-of-concept combination therapy trials in the near future. First, a more integrated understanding of the complex pathophysiology and progression of AD is needed to identify the appropriate pathways and the disease stage to target. Once drug candidates are identified, novel clinical trial designs and selection of appropriate outcome assessments will be needed to enable definition and evaluation of the appropriate dose and dosing regimen and determination of efficacy. Success in addressing this urgent problem will only be achieved through collaboration among multiple stakeholders.

Original languageEnglish
Pages (from-to)623-630
Number of pages8
JournalAlzheimer's and Dementia
Volume12
Issue number5
DOIs
StatePublished - May 1 2016

Fingerprint

Dive into the research topics of 'Challenges, solutions, and recommendations for Alzheimer's disease combination therapy'. Together they form a unique fingerprint.

Cite this